NEW YORK (GenomeWeb) – Startup microbiome-based technology firm Enterome said today that it raised €10 million ($13.9 million) in the first tranche of a Series B financing round.

The Paris-based company said that the funding will be used to conduct R&D and business activities. Its technology platform, called the Metagenotyping system, is for developing new tools, such as biomarkers and companion diagnostics, for managing diseases. Eventually, the platform will be used for developing therapeutics for inflammatory bowel and metabolic disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.